JP2008528617A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528617A5
JP2008528617A5 JP2007553278A JP2007553278A JP2008528617A5 JP 2008528617 A5 JP2008528617 A5 JP 2008528617A5 JP 2007553278 A JP2007553278 A JP 2007553278A JP 2007553278 A JP2007553278 A JP 2007553278A JP 2008528617 A5 JP2008528617 A5 JP 2008528617A5
Authority
JP
Japan
Prior art keywords
cancer
subject
composition
patient
multiple myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007553278A
Other languages
English (en)
Japanese (ja)
Other versions
JP5371246B2 (ja
JP2008528617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/002979 external-priority patent/WO2006081445A2/en
Publication of JP2008528617A publication Critical patent/JP2008528617A/ja
Publication of JP2008528617A5 publication Critical patent/JP2008528617A5/ja
Application granted granted Critical
Publication of JP5371246B2 publication Critical patent/JP5371246B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007553278A 2005-01-27 2006-01-27 転移した腫瘍の治療 Expired - Fee Related JP5371246B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US64756805P 2005-01-27 2005-01-27
US60/647,568 2005-01-27
US66924505P 2005-04-06 2005-04-06
US60/669,245 2005-04-06
US72205305P 2005-09-29 2005-09-29
US60/722,053 2005-09-29
PCT/US2006/002979 WO2006081445A2 (en) 2005-01-27 2006-01-27 Treatment of metastasized tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013129277A Division JP2013177464A (ja) 2005-01-27 2013-06-20 転移した腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2008528617A JP2008528617A (ja) 2008-07-31
JP2008528617A5 true JP2008528617A5 (enExample) 2009-01-29
JP5371246B2 JP5371246B2 (ja) 2013-12-18

Family

ID=36741085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007553278A Expired - Fee Related JP5371246B2 (ja) 2005-01-27 2006-01-27 転移した腫瘍の治療
JP2013129277A Withdrawn JP2013177464A (ja) 2005-01-27 2013-06-20 転移した腫瘍の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013129277A Withdrawn JP2013177464A (ja) 2005-01-27 2013-06-20 転移した腫瘍の治療

Country Status (22)

Country Link
US (2) US20060183750A1 (enExample)
EP (2) EP2301546B1 (enExample)
JP (2) JP5371246B2 (enExample)
KR (1) KR101387985B1 (enExample)
CN (1) CN103893181A (enExample)
AT (1) ATE526025T1 (enExample)
AU (1) AU2006208012B2 (enExample)
BR (1) BRPI0607285A2 (enExample)
CA (1) CA2596084A1 (enExample)
CY (1) CY1112570T1 (enExample)
DK (1) DK1845990T3 (enExample)
ES (2) ES2374570T3 (enExample)
IL (1) IL184866A0 (enExample)
MA (1) MA29266B1 (enExample)
MX (1) MX2007009099A (enExample)
NO (1) NO20074360L (enExample)
PL (2) PL1845990T3 (enExample)
PT (2) PT2301546E (enExample)
SG (1) SG173317A1 (enExample)
SI (1) SI2301546T1 (enExample)
TN (1) TNSN07294A1 (enExample)
WO (1) WO2006081445A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4341949B2 (ja) 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
AU2006247803B2 (en) * 2005-05-13 2011-12-22 Novartis Ag Methods for treating drug resistant cancer
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
WO2010135534A2 (en) * 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
US8741903B2 (en) * 2010-04-16 2014-06-03 Novartis Ag Organic compound for use in the treatment of hepatocellular cancer (HCC)
US20150182525A1 (en) * 2011-05-19 2015-07-02 Novartis Ag 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Quinolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma
MX2014009303A (es) * 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
US10730868B2 (en) * 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
IL127559A0 (en) 1996-06-20 1999-10-28 Univ Texas Compounds and methods for providing pharmacologically active preparations and uses thereof
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
WO2001029025A2 (en) * 1999-10-19 2001-04-26 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778417B2 (en) 2000-02-25 2004-12-02 Merck & Co., Inc. Tyrosine kinase inhibitors
JP4341949B2 (ja) * 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
BRPI0113757B8 (pt) * 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
EP2573079A3 (en) * 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
SG148864A1 (en) * 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
JP4823914B2 (ja) * 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
EP1718306A2 (en) * 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
US20060261307A1 (en) * 2005-05-18 2006-11-23 Black D J Water Activated Organic Scavenger
KR102639757B1 (ko) 2017-01-09 2024-02-23 엘지이노텍 주식회사 카메라 모듈 및 이를 포함하는 광학기기

Similar Documents

Publication Publication Date Title
AU2011302344B2 (en) HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
JP2013507415A5 (enExample)
JP2008528671A5 (enExample)
JP2012525393A5 (enExample)
JP2011518202A5 (enExample)
JP2013519632A5 (enExample)
JP2013513613A5 (enExample)
JP2015508103A5 (enExample)
JP2016526540A5 (enExample)
JP2020507589A5 (enExample)
JP2015536986A5 (enExample)
JP2005511556A5 (enExample)
JP2013540114A5 (enExample)
JP2009525981A5 (enExample)
JP2014505107A5 (enExample)
AU2022409798A1 (en) Use of combination therapy for treating cancer
JP2013511526A5 (enExample)
CA2596084A1 (en) Treatment of metastasized tumors with quinolinone benzimidazole compounds
JP2007518815A5 (enExample)
CN101484443A (zh) 放射线治疗增强剂
JP2009502777A5 (enExample)
JP2012528186A5 (enExample)
JP2012504584A5 (enExample)
JP2008525493A5 (enExample)
JP2013523867A5 (enExample)